JNK1 as a signaling node in VDR-BRAF induction of cell death in AML

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Clinical trials show limited benefits of vitamin D for cancer treatment.
• Preclinical data and epidemiological studies suggest potential anti-cancer properties of vitamin D compounds.
• Novel therapeutic strategies are needed to leverage vitamin D's potential in cancer therapy.

Purpose of the Study:

• To investigate a novel therapeutic strategy combining a vitamin D2 analog (Doxercalciferol) and Carnosic acid with standard chemotherapy for Acute Myeloid Leukemia (AML).
• To elucidate the molecular mechanisms underlying the enhanced efficacy of this combination therapy, focusing on key signaling pathways.

Main Methods:

• AML cells were treated with Cytarabine (AraC) followed by Doxercalciferol and Carnosic acid.
• The role of Vitamin D Receptor (VDR), BRAF kinase, and c-Jun N-terminal kinase (JNK) in cell death was assessed.
• Knock-down or inhibition of JNK was used to evaluate its contribution to the enhanced cell death.

Main Results:

• The combination therapy significantly enhanced AML cell death.
• Enhanced cell death was dependent on VDR and BRAF kinase activity.
• The stress-related kinase JNK was identified as a crucial mediator of enhanced cell death.
• JNK signaling to the apoptosis regulator BIM and Caspase executioners was found to be downstream of VDR and BRAF.

Conclusions:

• The combination of Doxercalciferol and Carnosic acid with AraC represents a promising strategy for enhancing AML treatment.
• JNK signaling plays a critical role in mediating the enhanced anti-leukemic effects observed in this protocol.
• Understanding these molecular pathways provides a basis for advancing this regimen towards clinical trials.